Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 948-085-1 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- dermal absorption, other
- Type of information:
- (Q)SAR
- Adequacy of study:
- key study
- Study period:
- 25.02.2019
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- results derived from a valid (Q)SAR model and falling into its applicability domain, with adequate and reliable documentation / justification
- Qualifier:
- according to guideline
- Guideline:
- other: REACH Guidance on QSAR R6
- Specific details on test material used for the study:
- SMILES:O=S(=O)(O{-}.[Na]{+})O{-}.[Na]{+}_O=S1(=O)O{-}.[Cu]{2+}.O{-}1_OCC{P-}(O)C{P-}(O)C{P+}(O)C{P-}(O)C(=O)O{-}.[Cu]{2+}.O{-}C(=O)C{P-}(O)C{P+}(O)C{P-}(O)C{P-}(O)CO
- Conclusions:
- The value obtained of the prediction was 5.14.
Reference
Description of key information
The value obtained of the prediction was 5.14 for toxicokinetics metabolism and distribution in dermal absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 5.14
- Absorption rate - inhalation (%):
- 100
Additional information
The following information is taken into account for any hazard / risk assessment:
Experimental toxicokinetic studies are not available. The log P of – 3.11 is not suggestive of accumulation of unchanged copper di-D-gluconate/copper (2+) bis(2,3,4,5,6-pentahydroxyhexanoate) in fatty tissues subsequent to absorption from gastro-intestinal tract or from lungs. However, on the basis of the molecular structure primarily elimination is expected through bile, with small amounts eliminated in urine, sweat, and epidermal shedding.
Elimination is assumed to be rapid according to the information provided on in silico studies: BAF (mid-trophic): -0.0277 log(L/kg wet)
Therefore, no potential for bioaccumulation is to be expected.
Additional information:
Assessment of oral toxicokinetics based on the physicochemical properties of copper di-D-gluconate / copper (2+) bis(2,3,4,5,6-pentahydroxyhexanoate):
- Molecular weight= 453.84 g/mol
- Water solubility= >1000 g/L
- Partition coefficient log P = -3.11
The following remarks on the toxicokinetics of copper di-D-gluconate / copper (2+) bis(2,3,4,5,6-pentahydroxyhexanoate) are based on the available studies. Experimental toxicokinetic studies were not available.
ABSORPTION
The physicochemical characteristics of copper di-D-gluconate / copper (2+) bis(2,3,4,5,6-pentahydroxyhexanoate) (log Pow -3.11) and the molecular mass suggest a low absorption from the gastro-intestinal tract subsequent to oral ingestion. Since only in silico data was generated for chronic toxicity, it was not possible to extrapolate an oral absorption value.
Therefore, a default oral absorption value of 100% was used.
N-octanol/water partition coefficient and molecular weight of copper di-D-gluconate / copper (2+) bis(2,3,4,5,6-pentahydroxyhexanoate) are not in ranges that favour dermal absorption.
It was confirmed by in silico studies.
DISTRIBUTION and METABOLISM
The structure of copper di-D-gluconate / copper (2+) bis(2,3,4,5,6-pentahydroxyhexanoate) suggests that after oral ingestion, it will be distributed and metabolised according to homeostasis. Liver is the major organ involved in copper homeostasis.
Once absorbed, the metal passes through basolateral membrane and transported to the liver bounded to the serum albumin, ceruloplasmin, or low-molecular mass complexes. In blood, copper is distributed into a nonexchangeable red cell pool, a plasma pool associated with proteins, and a labile pool of low molecular mass complexes. In humans, approximately 80-90% of the plasma copper is tightly bound with ceruloplasmin while the rest is bound to albumin and amino acids. intestinal copper uptake primarily occurs in the small intestine.
It will preferably be metabolized by biotransformation bounding to the carrier protein, metallothionein.
ELIMINATION
The n-Octanol/water partition coefficient (log Pow of -3.11) is suggestive of a high lipophobicity of copper di-D-gluconate / copper (2+) bis(2,3,4,5,6-pentahydroxyhexanoate) subsequent to absorption from gastrointestinal tract or from lungs. Rapid elimination is expected considering its BAF (mid-trophic) values (-0.0277 L/kg).
On the basis of the molecular structure excretion into bile is assumed to be a preferred route of elimination with small amounts eliminated though urine, sweat and epidermal shedding.
Therefore, no potential for bioaccumulation is to be expected.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
